A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

Source:http://linkedlifedata.com/resource/pubmed/id/16847470

Br. J. Cancer 2006 Aug 7 95 3 253-9

Download in:

View as

Triples

General Info

PMID
16847470